[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100497884":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":21,"locations":27,"responsibleParty":45,"collaborators":11,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":11,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":11,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":11,"overallStatus":30,"whyStopped":11,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Oregon Health and Science University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ferric derisomaltose","EXPERIMENTAL",null,[13],"Drug: Ferric derisomaltose",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Participants between the gestational ages of 14 to 42 weeks with iron deficiency will receive IV Ferric derisomaltose at a routine prenatal visit.",[9],[20],"Monoferric",[22],{"name":23,"role":24,"phone":25,"phoneExt":11,"email":26},"Women's Health Research Unit Research Unit Department of OB\u002FGyn","CONTACT","503-494-3666","whru@ohsu.edu",[28],{"facility":29,"status":30,"city":31,"state":32,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Oregon Health & Science Univerity","RECRUITING","Portland","Oregon","97239","United States","US",{"type":37,"coordinates":38},"Point",[39,40],-122.67621,45.52345,{"lat":40,"lon":39},[43],{"name":44,"role":24,"phone":25,"phoneExt":11,"email":26},"Women's Health Research Unit",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Ashley Benson","Principal Investigator","100497884","early-phase-1-monoferric-for-prenatal-iron-deficiency-100497884",false,"NCT05763043","Monoferric for Prenatal Iron Deficiency","Inclusion Criteria:\n\n* Participants 18 years of age or older between 14 to 42 weeks gestation who are deemed appropriate for IV iron by their treating provider as part of their standard of care treatment.\n* Iron deficiency anemia, defined as second or third trimester (14 weeks or more) hemoglobin less than or equal to 10.5 g\u002FdL or less than or equal to11 g\u002FdL, respectively, and ferritin less than 50 μg\u002FL\n* Experience intolerance to oral iron or are greater than 28 weeks gestation\n* Willing to participate in the study\n\nExclusion Criteria:\n\n* Known infectious, inflammatory, or malignant conditions that may confound iron repletion and outcome analysis\n* Prior IV iron intolerance or hypersensitivity reaction",true,"FEMALE","18 Years","65 Years",{"count":60,"type":61},80,"ESTIMATED","INTERVENTIONAL",[64],"EARLY_PHASE1","A prospective observational study of pregnant women with iron deficiency anemia and oral iron intolerance or advanced gestational age.",[67],"Obstetric Labor Complications","2024-09-16",{"date":70,"type":71},"2024-09-19","ACTUAL",{"date":73,"type":71},"2024-01-18",{"date":75,"type":61},"2028-10",{"name":5,"class":6},1]